The Small Lymphocytic Lymphoma Treatment Market was valued at USD 1.2 billion in 2024 and is projected to reach USD 2.5 billion by 2034, registering a CAGR of 7.5%. This growth trajectory is underpinned by several factors, including the rising incidence of small lymphocytic lymphoma (SLL), advancements in treatment modalities, and increasing healthcare expenditure. The demand for effective...